A phase II multicenter clinical trial assessing the safety and efficacy of ixazomib, pomalidomide and dexamethasone combination as second or third-line treatment for triple-class exposed patients with relapsed and refractory multiple myeloma (iPod-790 Trial) Meeting Abstract
| Authors: | Cohen, Y. C.; Shragai, T.; Lavi, N.; Vaxman, I.; Chubar, E.; Gatt, M. E.; Ganzel, C.; Magen, H.; Luttwak, E.; Mittelman, M.; Tzoran, I.; Vainstein, V.; Lowenton-Spier, N.; Melamed, N.; Krayzler, E.; Pereg, I.; Mazza, I. A. |
| Abstract Title: | A phase II multicenter clinical trial assessing the safety and efficacy of ixazomib, pomalidomide and dexamethasone combination as second or third-line treatment for triple-class exposed patients with relapsed and refractory multiple myeloma (iPod-790 Trial) |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 2014 |
| Language: | English |
| ACCESSION: | WOS:001159306707240 |
| DOI: | 10.1182/blood-2023-185830 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
